Nuveen
EVMN

Nuveen’s Evommune Inc EVMN Stock Holding History

Nuveen’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
20,899
+8,447
+68% +$196K ﹤0.01% 3529
2026
Q1 		$286K Buy
+12,452
New +$282K ﹤0.01% 3020

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Nuveen's EVMN Position: Q2 2026 in Review

Nuveen increased its Evommune Inc (EVMN) stake by 68% in Q2 2026, buying an estimated $196K and bringing the position to 20,899 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #3529.

Nuveen first reported a position in EVMN in Q1 2026 and has held it in 2 quarters since. The position peaked at $286K in Q1 2026. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Nuveen held 20,899 shares of Evommune Inc worth $278K as of Q2 2026.
  • Nuveen bought 8,447 Evommune Inc shares in Q2 2026, an estimated $196K.
  • Evommune Inc made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3529 holding.
  • Nuveen first reported a position in Evommune Inc in Q1 2026 and has held it in 2 quarters since.
  • Nuveen's Evommune Inc position peaked at $286K in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.